Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 448

1.

Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.

Ren C, Ren T, Yang K, Wang S, Bao X, Zhang F, Guo W.

J Exp Clin Cancer Res. 2016 Mar 11;35:44. doi: 10.1186/s13046-016-0321-3.

2.

R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.

Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R.

PLoS One. 2011;6(10):e26060. doi: 10.1371/journal.pone.0026060. Epub 2011 Oct 11.

3.

Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.

Boro A, Prêtre K, Rechfeld F, Thalhammer V, Oesch S, Wachtel M, Schäfer BW, Niggli FK.

Int J Cancer. 2012 Nov 1;131(9):2153-64. doi: 10.1002/ijc.27472. Epub 2012 Mar 29.

4.

Junction region of EWS-FLI1 fusion protein has a dominant negative effect in Ewing's sarcoma in vitro.

Jully B, Vijayalakshmi R, Gopal G, Sabitha K, Rajkumar T.

BMC Cancer. 2012 Nov 12;12:513. doi: 10.1186/1471-2407-12-513.

5.

Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1).

Subbiah V, Brown RE, Jiang Y, Buryanek J, Hayes-Jordan A, Kurzrock R, Anderson PM.

PLoS One. 2013 Jul 29;8(7):e68985. doi: 10.1371/journal.pone.0068985. Print 2013.

6.

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.

Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.

Sci Signal. 2017 Oct 3;10(499). pii: eaam8429. doi: 10.1126/scisignal.aam8429.

PMID:
28974650
7.

A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.

Leacock SW, Basse AN, Chandler GL, Kirk AM, Rakheja D, Amatruda JF.

Dis Model Mech. 2012 Jan;5(1):95-106. doi: 10.1242/dmm.007401. Epub 2011 Oct 6.

8.

FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.

Yang L, Hu HM, Zielinska-Kwiatkowska A, Chansky HA.

Biochem Biophys Res Commun. 2010 Nov 5;402(1):129-34. doi: 10.1016/j.bbrc.2010.09.129. Epub 2010 Oct 8.

9.

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.

Niedan S, Kauer M, Aryee DN, Kofler R, Schwentner R, Meier A, Pötschger U, Kontny U, Kovar H.

Oncogene. 2014 Jul 24;33(30):3927-38. doi: 10.1038/onc.2013.361. Epub 2013 Sep 2.

10.

Selective usage of D-Type cyclins by Ewing's tumors and rhabdomyosarcomas.

Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ.

Cancer Res. 2004 Sep 1;64(17):6026-34.

11.

Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.

Hensel T, Giorgi C, Schmidt O, Calzada-Wack J, Neff F, Buch T, Niggli FK, Schäfer BW, Burdach S, Richter GH.

Oncotarget. 2016 Jan 12;7(2):1451-63. doi: 10.18632/oncotarget.6385.

12.

MiR-125b inhibits cell biological progression of Ewing's sarcoma by suppressing the PI3K/Akt signalling pathway.

Li J, You T, Jing J.

Cell Prolif. 2014 Apr;47(2):152-60. doi: 10.1111/cpr.12093. Epub 2014 Feb 12.

PMID:
24517182
13.

EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.

Nagano A, Ohno T, Shimizu K, Hara A, Yamamoto T, Kawai G, Saitou M, Takigami I, Matsuhashi A, Yamada K, Takei Y.

Int J Cancer. 2010 Jun 15;126(12):2790-8. doi: 10.1002/ijc.24781.

14.

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.

Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK.

Oncotarget. 2015 Oct 6;6(30):28895-910. doi: 10.18632/oncotarget.5000.

15.

The dual inhibitory effect of thiostrepton on FoxM1 and EWS/FLI1 provides a novel therapeutic option for Ewing's sarcoma.

Sengupta A, Rahman M, Mateo-Lozano S, Tirado OM, Notario V.

Int J Oncol. 2013 Sep;43(3):803-12. doi: 10.3892/ijo.2013.2016. Epub 2013 Jul 12.

16.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678. Epub 2013 Aug 8.

17.

An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.

Winter GE, Rix U, Lissat A, Stukalov A, Müllner MK, Bennett KL, Colinge J, Nijman SM, Kubicek S, Kovar H, Kontny U, Superti-Furga G.

Mol Cancer Ther. 2011 Oct;10(10):1846-56. doi: 10.1158/1535-7163.MCT-11-0100. Epub 2011 Jul 18.

18.

Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.

Rao DD, Jay C, Wang Z, Luo X, Kumar P, Eysenbach H, Ghisoli M, Senzer N, Nemunaitis J.

Mol Ther. 2016 Aug;24(8):1412-22. doi: 10.1038/mt.2016.93. Epub 2016 May 11.

19.

High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.

Awad O, Yustein JT, Shah P, Gul N, Katuri V, O'Neill A, Kong Y, Brown ML, Toretsky JA, Loeb DM.

PLoS One. 2010 Nov 11;5(11):e13943. doi: 10.1371/journal.pone.0013943.

20.

Promiscuous partnerships in Ewing's sarcoma.

Sankar S, Lessnick SL.

Cancer Genet. 2011 Jul;204(7):351-65. doi: 10.1016/j.cancergen.2011.07.008. Review.

Supplemental Content

Support Center